Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database

被引：0
作者：
Stephanie H. Read
Nadia Quignot
Raissa Kapso-Kapnang
Erin Comerford
Ying Zheng
Corona Gainford
Medha Sasane
Anne-Lise Vataire
Laure Delzongle
Francois-Clement Bidard
机构：
[1] Certara UK Limited,Department of Medical Oncology
[2] Certara France,undefined
[3] Sanofi,undefined
[4] Sanofi,undefined
[5] Institut Curie,undefined
[6] Université Versailles Saint-Quentin,undefined
[7] Université Paris-Saclay,undefined
来源：
Breast Cancer Research and Treatment | 2024年 / 204卷
关键词：
Hormone receptor negative; Metastatic breast cancer; Endocrine therapy; Cyclin-dependent kinase 4/6 inhibitor; Real-world evidence; SNDS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：579 / 588
页数：9
相关论文
共 50 条
[21]   Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach [J].
Fontanella, Caterina ;
Giorgi, Carlo Alberto ;
Russo, Stefania ;
Angelini, Silvia ;
Nicolardi, Linda ;
Giarratano, Tommaso ;
Frezzini, Simona ;
Pestrin, Marta ;
Palleschi, Dario ;
Bolzonello, Silvia ;
Parolin, Veronica ;
Haspinger, Eva R. ;
De Rossi, Costanza ;
Greco, Filippo ;
Gerratana, Lorenzo .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
[22]   Comparison of healthcare resource utilization and costs of patients with HR+/HER2-advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors [J].
Burne, Rebecca ;
Balu, Sanjeev ;
Guerin, Annie ;
Bungay, Rebecca ;
Sin, Roxana ;
Paul, Mary Lisha .
JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) :806-815
[23]   Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2-Metastatic Breast Cancer in Postmenopausal Women in the USA [J].
Masurkar, Prajakta P. ;
Damgacioglu, Haluk ;
Deshmukh, Ashish A. ;
Trivedi, Meghana V. .
PHARMACOECONOMICS, 2023, 41 (06) :709-718
[24]   Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2-Metastatic Breast Cancer [J].
Zhao, Joseph J. ;
Fong, Khi Yung ;
Chan, Yiong Huak ;
Tey, Jeremy ;
Dawood, Shaheenah ;
Lee, Soo Chin ;
Finn, Richard S. ;
Sundar, Raghav ;
Lim, Joline S. J. .
CANCERS, 2023, 15 (18)
[25]   Targeted Therapy in HR+HER2-Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options [J].
Elfgen, Constanze ;
Bjelic-Radisic, Vesna .
CANCERS, 2021, 13 (23)
[26]   Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR+ breast cancer patients undergoing CDK4/6 treatment [J].
Dandachi, Nadia ;
Posch, Florian ;
Graf, Ricarda ;
Suppan, Christoph ;
Klocker, Eva Valentina ;
Muller, Hannah Deborah ;
Lindenmann, Jorg ;
Terbuch, Angelika ;
Heitzer, Ellen ;
Balic, Marija .
MOLECULAR ONCOLOGY, 2021, 15 (09) :2390-2400
[27]   Trends in HR plus metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2-and HER2+metastatic breast cancer [J].
Brufsky, Adam ;
Kwan, Marilyn L. ;
Sandin, Rickard ;
Stergiopoulos, Stella ;
Karanth, Siddharth ;
Cha-Silva, Ashley S. ;
Makari, Doris ;
Goyal, Ravi K. .
BREAST CANCER RESEARCH AND TREATMENT, 2024, 208 (02) :223-235
[28]   Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea [J].
Novick, Diego ;
Lee, Sae Young ;
Koo, Dong Hyun ;
Szende, Agota ;
Colman, Sam .
JOURNAL OF DRUG ASSESSMENT, 2022, 11 (01) :12-19
[29]   Circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2-metastatic breast cancer [J].
El Rassy, Elie ;
Abdayem, Pamela ;
Kattan, Joseph .
FUTURE ONCOLOGY, 2017, 13 (17) :1451-1453
[30]   Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2-metastatic breast cancer in the United States: A SEER-Medicare population-based study [J].
Goyal, Ravi K. ;
Chen, Hua ;
Abughosh, Susan M. ;
Holmes, Holly M. ;
Candrilli, Sean D. ;
Johnson, Michael L. .
CANCER, 2023, 129 (07) :1051-1063
12345